Related Experiment Videos
Stem cell transplantation in myocardial infarction
Michael S Lee1, Michael Lill, Raj R Makkar
1Division of Cardiology, St. Luke's-Roosevelt Hospital Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Reviews in Cardiovascular Medicine
|June 9, 2004
Summary
Stem cell therapy shows promise for treating heart failure after myocardial infarction by regenerating heart muscle. However, more large-scale clinical trials are needed to confirm its long-term safety and effectiveness.
Area of Science:
- Regenerative Medicine
- Cardiology
- Stem Cell Biology
Background:
- Congestive heart failure (CHF) is a leading cause of hospitalization in older adults, often resulting from myocardial infarction (MI).
- Current treatments for MI and subsequent CHF, such as pharmacotherapy, are insufficient in preventing adverse left ventricular remodeling.
- Stem cells offer a potential therapeutic avenue due to their ability to differentiate into cardiomyocytes.
Purpose of the Study:
- To explore cellular cardiomyoplasty as a regenerative approach for preventing left ventricular remodeling post-MI.
- To review the current evidence on stem cell transplantation for cardiac repair.
Main Methods:
- Review of preclinical animal studies on stem cell transplantation.
- Analysis of early-phase I clinical trial data for cellular cardiomyoplasty.
Main Results:
- Preclinical data suggest potential safety and efficacy of stem cell transplantation.
- Early clinical studies are limited in scope and preliminary in nature.
Conclusions:
- Cellular cardiomyoplasty presents a promising therapeutic strategy for post-MI cardiac regeneration.
- Robust data from large, randomized controlled trials are essential to establish the definitive short- and long-term outcomes of this approach.